Japanese rapid/living recommendations on drug management for COVID‐19
| العنوان: | Japanese rapid/living recommendations on drug management for COVID‐19 |
|---|---|
| المؤلفون: | Kazuma Yamakawa, Ryo Yamamoto, Go Ishimaru, Hideki Hashimoto, Takero Terayama, Yoshitaka Hara, Daisuke Hasegawa, Tadashi Ishihara, Haruki Imura, Hiromu Okano, Chihiro Narita, Takuya Mayumi, Hideto Yasuda, Kohei Yamada, Hiroyuki Yamada, Tatsuya Kawasaki, Nobuaki Shime, Kent Doi, Moritoki Egi, Hiroshi Ogura, Morio Aihara, Hiroshi Tanaka, Osamu Nishida, the Special Committee of the Japanese Clinical Practice Guidelines for the Management of Sepsis and Septic Shock 2020 (J‐SSCG 2020), the COVID‐19 Task Force |
| المصدر: | Acute Medicine & Surgery, Vol 8, Iss 1, Pp n/a-n/a (2021) Acute Medicine & Surgery |
| بيانات النشر: | Wiley, 2021. |
| سنة النشر: | 2021 |
| مصطلحات موضوعية: | medicine.medical_specialty, Rapid Publication, Ciclesonide, 030204 cardiovascular system & hematology, Sepsis, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Tocilizumab, Intensive care, medicine, 030212 general & internal medicine, GRADE approach, SIRS‐CoV‐2, evidence‐based medicine, Septic shock, business.industry, RC86-88.9, practice guideline, General Engineering, Hydroxychloroquine, Medical emergencies. Critical care. Intensive care. First aid, Evidence-based medicine, Guideline, medicine.disease, Coronavirus, chemistry, Emergency medicine, business, medicine.drug |
| الوصف: | The Coronavirus disease 2019 (COVID‐19) has spread worldwide since early 2020, and there are still no signs of resolution. The Japanese Clinical Practice Guidelines for the Management of Sepsis and Septic Shock (J‐SSCG) 2020 Special Committee created the Japanese Rapid/Living recommendations on drug management for COVID‐19 using the experience of creating the J‐SSCGs. The Grades of Recommendation, Assessment, Development, and Evaluation (GRADE) approach was used to determine the certainty of the evidence and strength of the recommendations. The first edition of this guideline was released on September 9, 2020, and this document is the revised edition (ver. 3.1) (released on March 30, 2021). Clinical questions (CQs) were set for the following seven drugs: favipiravir (CQ1), remdesivir (CQ‐2), hydroxychloroquine (CQ‐3), corticosteroids (CQ‐4), tocilizumab (CQ‐5), ciclesonide (CQ‐6), and anticoagulants (CQ‐7). Favipiravir is recommended for patients with mild COVID‐19 not requiring supplemental oxygen (GRADE 2C); remdesivir for moderate COVID‐19 patients requiring supplemental oxygen/hospitalization (GRADE 2B); hydroxychloroquine is not recommended for all COVID‐19 patients (GRADE 1B); corticosteroids are recommended for moderate COVID‐19 patients requiring supplemental oxygen/hospitalization (GRADE 1B) and severe COVID‐19 patients requiring ventilator management/intensive care (GRADE 1A); however, their administration is not recommended for mild COVID‐19 patients not requiring supplemental oxygen (GRADE 1B); tocilizumab is recommended for moderate COVID‐19 patients requiring supplemental oxygen/hospitalization (GRADE 2B); and anticoagulant therapy for moderate COVID‐19 patients requiring supplemental oxygen/hospitalization and severe COVID‐19 patients requiring ventilator management/intensive care (GRADE 2C). We hope that these clinical practice guidelines will aid medical professionals involved in the care of COVID‐19 patients. |
| اللغة: | English |
| تدمد: | 2052-8817 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ef76bdc9233c04a22d30e63fa49b4bb4Test https://doaj.org/article/11e1cce46ab84eb191ce22b2eed691eaTest |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....ef76bdc9233c04a22d30e63fa49b4bb4 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 20528817 |
|---|